SemaShape Weight Loss Clinic

SemaShape Weight Loss Clinic opened in Shreveport, Louisiana in 2023 to address the growing demand for medically supervised weight loss programs utilizing GLP-1 receptor agonist medications. The clinic focuses exclusively on prescription weight management, offering evidence-based pharmaceutical interventions rather than general wellness services. Located in Shreveport and serving patients throughout Louisiana and Texas, SemaShape provides both in-person consultations at their Shreveport facility and telehealth appointments for established patients across their service area.

The clinic's treatment protocol centers on two FDA-approved GLP-1 medications: semaglutide and liraglutide. Semaglutide, administered as a once-weekly subcutaneous injection, mimics the glucagon-like peptide-1 hormone to regulate appetite and slow gastric emptying. Liraglutide follows a similar mechanism with daily injection dosing. Both medications have demonstrated significant weight reduction in clinical trials when combined with lifestyle modification. SemaShape's prescribers evaluate patient medical history, current medications, and contraindications including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 before initiating therapy. The clinic does not offer compounded versions of these medications, working exclusively with FDA-approved pharmaceutical formulations.

Patients beginning treatment at SemaShape Weight Loss Clinic undergo an initial consultation that includes review of weight history, previous weight loss attempts, comorbid conditions such as type 2 diabetes or hypertension, and realistic goal setting. The clinic's approach involves titration protocols that gradually increase medication dosing to minimize gastrointestinal side effects commonly associated with GLP-1 agonists. Providers monitor patient response through regular follow-up appointments, adjusting dosages based on tolerance and weight loss progress. The Shreveport clinic emphasizes that these medications work most effectively when patients simultaneously implement dietary changes and increase physical activity, though they do not provide in-house nutrition counseling or exercise programming.

SemaShape's hybrid consultation model allows Louisiana and Texas residents to access care through the method that best fits their schedule and location. Initial consultations typically occur in person at the Shreveport clinic, where providers can conduct physical assessments and establish baseline measurements. Follow-up appointments for medication management, dose adjustments, and progress monitoring are available via telehealth for patients who have completed their initial evaluation. This flexibility has proven particularly valuable for patients in rural areas of Louisiana and East Texas who would otherwise face significant travel barriers to accessing prescription weight loss treatment. The clinic maintains a 4.4-star rating from seven Google reviews, with patients noting the thoroughness of goal-setting discussions during consultations.

As a specialized weight management practice, SemaShape Weight Loss Clinic does not treat other conditions or offer additional peptide therapies beyond their two GLP-1 medications. This focused approach allows the clinic to maintain expertise specifically in semaglutide and liraglutide prescribing, including management of common side effects, appropriate patient selection, and coordination with patients' primary care providers. The clinic requires patients to have a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity, consistent with FDA labeling for these medications. Patients interested in treatment can schedule consultations through the clinic's website, with availability for both Shreveport-area residents seeking in-person care and those throughout Louisiana and Texas preferring hybrid care models.